Skip to main content

MPM Bioventures 2018, L.P.'s Form 4 filing

Entrada Therapeutics, Inc. (TRDA) · filed Aug 31, 2026

Accession no.
0001231919-26-001136
Filed
Aug 31, 2026, 6:26 PM ET
Trade date
Aug 27-31, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 3 non-derivative transactions. Open-market sales total $615.8K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
MPM Bioventures 2018, L.P.CIK 000172950510% Owner
MPM BioVentures 2018 GP LLCCIK 000181870110% Owner
MPM BioVentures 2018 LLCCIK 000181870210% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 27, 2026Common StockSSaleDisposed−38,922$7.20F2−$280,238.44,279,426IndirectDuplicate filing
Aug 28, 2026Common StockSSaleDisposed−3,733$7.01F6−$26,168.334,275,693IndirectDuplicate filing
Aug 31, 2026Common StockSSaleDisposed−44,259$6.99F9−$309,370.414,231,434IndirectDuplicate filing

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.88 to $7.37 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Referenced by the price of 1 transaction in Table I.

F6

Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.95 to $7.24 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Referenced by the price of 1 transaction in Table I.

F9

Price represents the weighted average sale price of the shares sold. The sale price ranged from $6.76 to $7.1626 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Referenced by the price of 1 transaction in Table I.

Remarks

See Form 4 for MPM BioVentures 2014, L.P for additional members of this joint filing.

Read the full filing on SEC EDGAR (opens in a new tab)